Key statistics dashboard for aTyr Pharma, Inc. (ATYR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2.
Stock Data
| Price | $0.38 |
| Market Cap | $38M |
| Beta | 0.65 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.62 |
| Price / Book | 0.78 |
| P/S | 199.61 |
| P/FCF | -0.69 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -11754.74% |
| EBIT Margin | -32005.26% |
| EBITDA Margin | -30812.63% |
| Operating Margin | -33609.47% |
| Net Margin | -32003.68% |
Financial Health
| Current Ratio | 5.12 |
| Quick Ratio | 5.12 |
| Cash Ratio | 1.42 |
| Debt / Equity | 0.23 |
| Debt / Assets | 16.18% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -9.28 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.50 |
| Cash per share | 0.59 |
| FCF per share | -0.56 |
| Tangible Book Value per share | 0.50 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.30 |
Related companies: ACRV · ALXO · CAMP · DTIL · HYFT · MGX · QNCX
Explore sector: Healthcare · Biotechnology
More sections of ATYR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks